{"id":"W3203041075","doi":"10.1016/j.annonc.2021.08.058","title":"662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Renal cell carcinoma; Oncology; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009694139,0.0004193427,0.0006895395,0.0002943545,0.0004183965,0.0008772413,0.0004646549,0.0003550278,0.003027089],"category_scores_gemma":[0.001029486,0.0002326598,0.0009031145,0.000460605,0.0001913406,0.0006043109,0.0004382241,0.0008960954,0.000930146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008832891,"about_ca_system_score_gemma":0.001114393,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008323005,"about_ca_topic_score_gemma":0.0145451,"domain_scores_codex":[0.9996124,0.00008757439,0.00001999785,0.0001136915,0.00007321735,0.00009322939],"domain_scores_gemma":[0.9993383,0.0000768369,0.0001649674,0.0001089137,0.0001023519,0.0002086213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2048838,0.007824655,0.5945669,0.0007408982,0.005870753,0.0004101853,0.0004398515,0.002627524,0.01435457,0.0003063959,0.04700514,0.1209693],"study_design_scores_gemma":[0.01483612,0.01697485,0.9477085,0.0001240442,0.002061184,0.0004797179,0.0002804977,0.001041209,0.002200179,0.0002272361,0.014018,0.00004833252],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9692601,0.00106565,0.0002214857,0.0002691447,0.00006677285,0.0002610899,0.02603427,0.00004398797,0.002777491],"genre_scores_gemma":[0.9316687,0.001128544,0.0005883857,0.0005159763,0.00009158398,0.00037041,0.06080511,0.0000503839,0.004780831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008323005,"threshold_uncertainty_score":0.01654911,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03387022440427974,"score_gpt":0.3120583596990088,"score_spread":0.2781881352947291,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}